The United States will distribute 60 million doses of the AstraZeneca COVID-19 vaccine to other countries over the next several months; workplace safety rules on COVID-19 submitted by Labor Department for review; White House reportedly will not include measures targeting drug prices in antipoverty package.
As reported by NPR, the White House announced yesterday during a press briefing that the United States will distribute 60 million doses of the AstraZeneca (AZ) COVID-19 vaccine to other countries over the next several months. Yet to be authorized in the United States while awaiting safety reviews by the FDA, the US government has previously sent excess AZ vaccines from its stockpile to Canada and Mexico. The White House did not specify which countries would receive the added shipments of the AZ vaccine, which has been shown to be 76% effective at preventing symptomatic COVID-19.
After setting a March 15 deadline to the Labor Department to decide whether mandatory workplace safety rules to protect workers against COVID-19 were warranted, the department sent the safety standards to the Office of Management and Budget (OMB) for review yesterday after weeks of delay and growing pressure from Democrats and safety advocates. POLITICO reports that the OMB’s Office of Information and Regulatory Affairs is expected to take 2 weeks before it publishes the requirements, which are expected to require employers to supply their workers with masks, have a written plan to prevent exposure, and take other precautions.
The White House is not planning to include any prescription drug pricing proposals sought by Democrats in Biden’s legislative package to address poverty, according to The Wall Street Journal. The paper reported that the antipoverty package will include funds for supporting the Affordable Care Act.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
2 Commerce Drive
Cranbury, NJ 08512